Aker Christopher's Insider Trades & SAST Disclosures
Aker Christopher's most recent trade in Regulus Therapeutics Inc was a trade of 487,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 30, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Aker Christopher.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regulus Therapeutics Inc | Christopher Aker | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 487,500 | 487,500 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Christopher Aker | Sr. VP & General Counsel | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 13 Jan 2025 | 38,547 | 54,634 (0%) | 0% | 1.3 | 48,693 | Common Stock |
| Regulus Therapeutics Inc | Christopher Aker | Sr. VP & General Counsel | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 13 Jan 2025 | 5,088 | 49,546 (0%) | 0% | 1.3 | 6,427 | Common Stock |
| Regulus Therapeutics Inc | Christopher Aker | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 363,000 | 363,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Aker Christopher | Sr. VP & General Counsel | Sale of securities on an exchange or to another person at price $ 1.19 per share. | 18 Jan 2024 | 5,468 | 10,056 (0%) | 0% | 1.2 | 6,510 | Common Stock |
| Regulus Therapeutics Inc | Aker Christopher | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Aker Christopher | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2024 | 11,250 | 15,524 (0%) | 0% | 0 | Common Stock | |
| Regulus Therapeutics Inc | Christopher Aker | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 393,750 | 393,750 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Christopher Aker | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2023 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Christopher Aker | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Christopher Aker | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2022 | 480,000 | 480,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Christopher Aker | Sr. VP & General Counsel | Sale of securities on an exchange or to another person at price $ 0.89 per share. | 17 May 2021 | 860 | 41,754 (0%) | 0% | 0.9 | 765 | Common Stock |
| Regulus Therapeutics Inc | Christopher Aker | Sr. VP & General Counsel | Sale of securities on an exchange or to another person at price $ 1.72 per share. | 16 Feb 2021 | 828 | 42,614 (0%) | 0% | 1.7 | 1,424 | Common Stock |
| Regulus Therapeutics Inc | Christopher Aker | Sr. VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Christopher Aker | Sr. VP & General Counsel | Sale of securities on an exchange or to another person at price $ 0.61 per share. | 14 Aug 2020 | 872 | 26,638 (0%) | 0% | 0.6 | 528 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges